

**CELLECT BIOMED**

www.cellectbio.com

**An innovative technology for the functional selection of stem cells**

Cellect Biotechnology is developing a platform technology for the functional selection of stem cells based on their resistance to apoptotic signals. Extensive lab studies on bone marrow, cord blood and fat cells have demonstrated a significant increase in stem cell concentration while eliminating toxic mature cells. Tested *in vivo*, these results represent improvements to the safety and efficacy of transplantations. Cellect's functional stem cell selection also improves the efficiency of any stem cell based treatment, while reducing the toxicity, resulting in better productivity during the manufacturing process for stem cell based products.

The company's first product line is a series of unique biocompatible cell selection containers internally coated with molecules that create an apoptosis-inducing microenvironment. These containers will be targeted for use in bone marrow transplants for cancer patients. Cellect also intends to market its containers to research laboratories and companies that manufacture stem cell based products.

**Contact details**

Shai Yarkoni, CEO | 20 Ha'Taas Street, Kfar Saba 4442520, Israel  
Tel: +972 (0)9 974 1444 | Email: info@cellectbio.com



**CELONIC**

www.celonic.com

**Celonic SEFEX: A GMP CHO-K1 cell line kit for drug developers and service providers**

SEFEX is a royalty-free cell line kit based on CHO-K1 cells. The ready-to-go kit includes cells, plasmids and detailed protocols for the handling, selection and screening process of drugs. Celonic provides the full service; from technical support and regulatory advice, through to process development and GMP manufacturing, Celonic is there for you.

The powerful SEFEX platform can be used throughout the entire product development process from laboratory cultures to production scale. SEFEX is robust, highly performing, and easy to implement. By using SEFEX you are guaranteed maximum productivity, substantial cost savings, and scale-up stability for increased project safety. Celonic also warrants that SEFEX-based production cell lines can be transferred to GMP environments.

Celonic's SEFEX delivers to you a scalable, highly efficient cell line kit to decrease your biologics development risk. Contact us today to learn more about how to access SEFEX.

**Contact details**

Ole Fuetterer, Senior Director Sales & Marketing  
Eulerstraße 55, 4051 Basel, Switzerland  
Tel: +41 (0)61 56 49 159 | Email: ole.fuetterer@celonic.ch



**HITGEN LTD**

www.hitgen.com

**HitGen – OpenDEL**

**Making encoded library technology a viable alternative to HTS**

HitGen's new OpenDEL encoded library of over 145 million small molecules, all with drug-like properties, can be screened using only 2 mg of target protein, at costs comparable to HTS on much smaller decks. The OpenDEL library is based on 70 different templates and is designed for high diversity within drug-like space.

OpenDEL is just one of the encoded library collections available for screening at HitGen; the other libraries, including the Macrocyclic Lead-Finder library, have demonstrated the ability to generate exciting hits even for challenging targets such as PPIs.

**Contact details**

Jin Li, CEO | F7-10, Building B3, Tianfu Life Science Park,  
88 South Keyuan Road, Chengdu 610041, Sichuan, China  
Tel: +86 288 519 7385 | Email: leadgen.info@hitgen.com



**Harnessing the power of Encoded Library Technology for your new targets**

**BRAINWAVE-DISCOVERY LTD**

www.brainwave-discovery.com

**Non-mammalian Alzheimer's, Parkinson's and Huntington's neurodegeneration tests**

*Early-stage drug screening.* Brainwave-Discovery provides medium throughput drug screening in early stage drug discovery for Alzheimer's, Parkinson's and Huntington's diseases. The *Drosophila* and human systems have been shown to have great similarity, and our in-house *humanised* models include hAPP/htau, htau, hAβ42, halpha synuclein and hLRRK2, with familial mutant forms. This is a fast and cost effective way to find new active chemicals or test chemicals between HTS and mammalian studies. We can provide these screens as a service or as a co-development opportunity.

*Personalised neurodegeneration models.* Key Alzheimer's and Parkinson's genes have many variants with potentially different neurodegenerative mechanisms. Our established humanisation approach offers a way of testing candidate drugs against a much wider range of disease alleles, increasing the likelihood of clinical success by matching to patients with the particular mutation.

*Other CNS diseases.* Brainwave-Discovery offers a custom humanised model production service for many human CNS diseases.

**Contact details**

Dr. Joanna Young (Europe, Asia) or Matt Mahoney (Americas) |  
Email: j.young@brainwave-discovery.com | m.mahoney@brainwave-discovery.com

